OVERVIEW

Exploring the Clinical Benefits of Antiviral Therapy in Decreasing Complications Associated with the Influenza Virus is organized by Pharmacy Times Continuing Education (PTCE). This Conference has been approved for a maximum of 1.5 contact hours (0.15 CEUs).

Release Date: April 12, 2019
Expiration Date: April 12, 2020

Target Audience: Retail pharmacists
Fee: Free

Program Description:
Data have shown that the use of antiviral treatment in the early stages of influenza can decrease the duration of fever and illness symptoms and can even lessen the risk of complications associated with influenza. New drug approvals create opportunities to effectively and safely treat influenza. Pharmacists should identify patients who may have influenza or who are at a high risk and be able to manage these patients’ influenza to diminish associated complications, hospitalizations, and mortality rates.

Educational Objectives:
At the completion of this activity, the participant will be able to:
• Explore the etiology, pathophysiology, and patient populations at high risk for influenza-related complications
• Explain the mechanisms of action and adverse effect profiles of available and recently approved antivirals for the treatment of the influenza virus
• Identify the role of the community pharmacist in educating patients about the available and recently approved antivirals for treatment of the influenza virus

Additional details will be posted as soon as information is available.